Sanofi and Teva Announce Maintenance Results for Duvakitug
Sanofi and Teva have announced positive phase IIb maintenance results for duvakitug, a monoclonal antibody targeting TL1A, in the treatment of ulcerative colitis and Crohn's disease. These data come from the RELIEVE UCCD program, a randomized double-blind clinical study conducted in various regions around the world.
Overview of the RELIEVE UCCD Program
The RELIEVE UCCD program includes a 14-week induction study and a long-term extension assessing duvakitug in adult patients with moderate to severe ulcerative colitis or Crohn's disease. The induction phase results demonstrated a clinically significant response of duvakitug compared to placebo at week 14. The 44-week maintenance period, involving 130 patients who responded to the induction phase, showed sustained clinical and endoscopic efficacy in patients with these two forms of chronic inflammatory bowel disease (IBD). Patients were randomized to receive a subcutaneous dose of 450 mg or 900 mg of duvakitug every four weeks. Both doses were well tolerated, with a safety profile consistent with the induction study.
Joint Development and Commercialization by Teva and Sanofi
Teva and Sanofi are jointly developing and commercializing duvakitug for ulcerative colitis and Crohn's disease. Sanofi is leading the ongoing phase III clinical development program. Teva will handle the commercialization in Europe, Israel, and certain other countries, while Sanofi will manage it in North America, Japan, Asia, and the rest of the world. Both companies equally share the development costs, as well as the profits and net losses in major markets. Additional indications for duvakitug are expected to be announced in 2026.
